Coherus Oncology (CHRS) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$50.9M

Revenue (quarter)

$14.3M

Revenue growth (year over year)

+39.53%

Gross profit (trailing twelve months)

$35.1M

Gross margin

68.94%

Net income (trailing twelve months)

−$132.1M

Net income (quarter)

−$20.6M

Net income growth (year over year)

−106.93%

Net margin

−259.41%

Return on equity

−146.27%

EPS (trailing twelve months)

−$1.05

Book value per share

$0.39

P/E (trailing twelve months)

—

Price to book

2.72

Debt to assets

68.18%

Payout ratio

—

Dividend yield

—

Company profile

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

• Is Coherus Oncology (CHRS) profitable?

  No. Coherus Oncology reported a net loss of $132.1M over the trailing twelve months.

• How much revenue does Coherus Oncology (CHRS) make?

  Coherus Oncology generated $50.9M in revenue over the trailing twelve months, up 39.53% year over year.

• How do I buy stock in Coherus Oncology (CHRS)?

  CHRS trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.